The estimated Net Worth of Michael J Malecek is at least $2.39 million dollars as of 27 September 2023. Mr. Malecek owns over 5,000 units of Prothena plc stock worth over $104,650 and over the last 5 years he sold PRTA stock worth over $0. In addition, he makes $2,289,020 as Chief Legal Officer and Company Secretary at Prothena plc.
Michael has made over 12 trades of the Prothena plc stock since 2021, according to the Form 4 filled with the SEC. Most recently he exercised 5,000 units of PRTA stock worth $51,350 on 27 September 2023.
The largest trade he's ever made was exercising 85,000 units of Prothena plc stock on 26 October 2022 worth over $872,950. On average, Michael trades about 8,889 units every 39 days since 2019. As of 27 September 2023 he still owns at least 5,000 units of Prothena plc stock.
You can see the complete history of Mr. Malecek stock trades at the bottom of the page.
Michael J. Malecek J.D. serves as Chief Legal Officer and Company Secretary of the Company. Prior to joining Prothena in 2019, he was Vice President, Deputy General Counsel, Intellectual Property and Litigation of Snowflake (a data warehouse company) from 2018. From 2010 to 2018, he was a Partner at Arnold & Porter Kaye Scholer LLP. From 2008 to 2010 Mr. Malecek was Partner at Dewey & LeBoeuf, LLP. From 2002-2008, he was Vice President and Chief Advocacy Counsel at Affymetrix (a biotechnology company). Mr. Malecek earned his BA in American Studies from Yale University and his JD (law degree) from the University of Virginia School of Law.
As the Chief Legal Officer and Company Secretary of Prothena plc, the total compensation of Michael Malecek at Prothena plc is $2,289,020. There are 2 executives at Prothena plc getting paid more, with Wagner Zago having the highest compensation of $3,341,640.
Michael Malecek is 54, he's been the Chief Legal Officer and Company Secretary of Prothena plc since 2019. There are 13 older and 11 younger executives at Prothena plc. The oldest executive at Prothena Corporation plc is Christopher Henney, 78, who is the Independent Director.
Michael's mailing address filed with the SEC is C/O PROTHENA BIOSCIENCES INC, 1800 SIERRA POINT PARKWAY, BRISBANE, CA, 94005.
Over the last 12 years, insiders at Prothena plc have traded over $79,429,035 worth of Prothena plc stock and bought 2,987,732 units worth $75,619,043 . The most active insiders traders include Capital, Llc Eco R1, Co Plc Elan Corp Plc Elan S... et Helen Susan Kim. On average, Prothena plc executives and independent directors trade stock every 21 days with the average trade being worth of $946,769. The most recent stock trade was executed by Karin L Walker on 24 January 2024, trading 5,000 units of PRTA stock currently worth $67,650.
prothena corporation plc (nasdaq: prta) is a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapy programs for the potential treatment of diseases that involve amyloid or cell adhesion. the company focuses on therapeutic monoclonal antibodies directed specifically to disease-causing proteins, and its antibody-based product candidates target a number of potential indications, including al amyloidosis (neod001), parkinson’s disease and other related synucleinopathies (prx002), and novel cell adhesion targets involved in psoriasis and other inflammatory diseases (prx003). our lead program, neod001, is in a global phase 3 registration clinical trial – the vital amyloidosis study. there is also an on-going phase 1/2 trial. prx002 is in a phase 1 multiple ascending dose clinical trial, and prx003 is in a phase 1 single ascending dose clinical trial. prothena’s elite team has a recognized track record both f
Prothena plc executives and other stock owners filed with the SEC include: